Left ventricular ejection fraction is associated with prevalent and incident cardiovascular disease in patients with intermittent claudication - results from the CAVASIC Study.
暂无分享,去创建一个
F. Kronenberg | G. Fraedrich | B. Rantner | B. Kollerits | P. Klein-Weigel | M. Stadler | Johannes Pohlhammer | S. Peric | A. Hammerer-Lercher
[1] P. Hedberg,et al. Left ventricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease , 2014, European journal of heart failure.
[2] E. Herrmann,et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. , 2014, Journal of the American College of Cardiology.
[3] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[4] F. Kronenberg,et al. Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: results from the CAVASIC study. , 2013, Clinical chemistry.
[5] David M. Herrington,et al. Prognosis of Individuals With Asymptomatic Left Ventricular Systolic Dysfunction in the Multi-Ethnic Study of Atherosclerosis (MESA) , 2012, Circulation.
[6] Eric E. Smith,et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standar , 2012, Circulation.
[7] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[8] A. Khera,et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. , 2010, JAMA.
[9] Jeroen J. Bax,et al. Influence of left ventricular dysfunction (diastolic versus systolic) on long-term prognosis in patients with versus without diabetes mellitus having elective peripheral arterial surgery. , 2010, The American journal of cardiology.
[10] A. Khera,et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. , 2009, American heart journal.
[11] William T. Abraham,et al. Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .
[12] O. Wagner,et al. Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study. , 2009, Clinical chemistry.
[13] F. Kronenberg,et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. , 2008, Clinical chemistry.
[14] P. Pellikka,et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. , 2007, Journal of vascular surgery.
[15] Jeroen J. Bax,et al. Improving risk assessment with cardiac testing in peripheral arterial disease. , 2007, The American journal of medicine.
[16] R. Lang,et al. Comparison of the frequency of abnormal cardiac findings by echocardiography in patients with and without peripheral arterial disease. , 2007, The American journal of cardiology.
[17] J. Rehfeld,et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. , 2006, European heart journal.
[18] F. Kronenberg,et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. , 2006, European heart journal.
[19] M. Chiariello,et al. Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study , 2006, Journal of cardiovascular medicine.
[20] S. Yusuf,et al. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. , 2006, Journal of the American College of Cardiology.
[21] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[22] J. Min,et al. High prevalence of important cardiac findings in patients with peripheral arterial disease referred for echocardiography. , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[23] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[24] K. Khunti,et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. , 2005, Journal of the American College of Cardiology.
[25] P. Shekelle,et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. , 2004, Journal of the American College of Cardiology.
[26] D. Levy,et al. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.
[27] Douglas W Mahoney,et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.
[28] Daniel Levy,et al. Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.
[29] D. Levy,et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.
[30] R. Rutherford,et al. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.
[31] D. Mann,et al. Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.
[32] M. Jensen-Urstad,et al. Comparison of different echocardiographic methods with radionuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy. , 1998, The American journal of cardiology.
[33] N. Kennedy,et al. Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. , 1996, The American journal of cardiology.
[34] G. Thorgeirsson,et al. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol--the Reykjavik Study. , 1994, Journal of clinical epidemiology.
[35] E. Vicaut,et al. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery. , 1994, The New England journal of medicine.
[36] G. Lamas,et al. Ventricular remodeling after myocardial infarction. , 1993, Advances in experimental medicine and biology.
[37] E. Rose,et al. Prognostic value of noninvasive cardiac tests in the assessment of patients with peripheral vascular disease. , 1993, The American journal of cardiology.
[38] B. Pitt,et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.
[39] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[40] J. Ricco. Intermittent claudication, heart disease risk factors, and mortality: Smith GD, Shipley MJ, Rose G. Circulation 1990;82: 1925–1931 , 1992 .
[41] M J Shipley,et al. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. , 1990, Circulation.
[42] M. Pfeffer,et al. Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.
[43] R. Schwartz,et al. Superiority of visual versus computerized echocardiographic estimation of radionuclide left ventricular ejection fraction. , 1989, American heart journal.
[44] M. Bousser,et al. Fate of the patient with chronic leg ischaemia. A review article. , 1989, The Journal of cardiovascular surgery.
[45] Jain Km,et al. Preoperative cardiac screening before peripheral vascular operations. , 1985 .
[46] N. Hertzer,et al. Coronary Artery Disease in Peripheral Vascular Patients: A Classification of 1000 Coronary Angiograms and Results of Surgical Management , 1984, Annals of surgery.